Adverse symptoms during short‐term use of ulipristal acetate in women with uterine myomas and/or adenomyosis

Aim To evaluate various adverse symptoms during short‐term use of ulipristal acetate in women with uterine myomas (n = 90), adenomyosis (n = 3) or both (n = 7). Methods One hundred premenopausal women who received ulipristal acetate for 4–12 weeks during 2016 to 2017 were selected. The medical recor...

Full description

Saved in:
Bibliographic Details
Published in:The journal of obstetrics and gynaecology research 2019-04, Vol.45 (4), p.865-870
Main Authors: Hong, Yeon Hee, Han, Soo Jin, Lee, Dayong, Kim, Seul Ki, Jee, Byung Chul
Format: Article
Language:English
Subjects:
Acetic acid
adenomyosis
adverse symptom
Amenorrhea
discontinuation
Fatigue
Headache
Hemoglobin
Liver
Medical records
Menstruation
myoma
Pain
Progestin
Smell
ulipristal acetate
Uterus
Vagina
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim To evaluate various adverse symptoms during short‐term use of ulipristal acetate in women with uterine myomas (n = 90), adenomyosis (n = 3) or both (n = 7). Methods One hundred premenopausal women who received ulipristal acetate for 4–12 weeks during 2016 to 2017 were selected. The medical records were reviewed and the following information was collected; adverse symptoms during medication, presence of menorrhagia or menstrual cramps, blood hemoglobin and liver function test. Adverse symptoms were recorded in the medical records as a checklist form including 76 specific progestin‐related symptoms. Results Overall, the most frequent adverse symptom was amenorrhea (43%), followed by weight gain (29%), fatigue (27%), abdominal discomfort (21%), decreased menstrual flow (19%) and dizziness (18%). In 89 symptomatic women (with heavy menstrual bleeding and/or menstrual cramping pain and/or anemia), the most frequent adverse symptom was weight gain (27%) and fatigue (27%), followed by abdominal discomfort (21%), dry eye (18%), facial flushing (17%), dizziness (17%), headache (17%) and increased vaginal discharge (15%). Fourteen women stopped the medication due to unwanted adverse symptoms. Of this discontinuation group, major complaint was fatigue (50%), followed by weight gain (36%) and breast discomfort (35.7%). Conclusion Adverse symptoms were common and discontinuation rate was somewhat higher during short‐term course of ulipristal acetate. Information about incidence of various adverse symptoms should be given to women who willing to take ulipristal acetate.
ISSN:1341-8076
1447-0756
DOI:10.1111/jog.13917